RU2007143434A - 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний - Google Patents
4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний Download PDFInfo
- Publication number
- RU2007143434A RU2007143434A RU2007143434/14A RU2007143434A RU2007143434A RU 2007143434 A RU2007143434 A RU 2007143434A RU 2007143434/14 A RU2007143434/14 A RU 2007143434/14A RU 2007143434 A RU2007143434 A RU 2007143434A RU 2007143434 A RU2007143434 A RU 2007143434A
- Authority
- RU
- Russia
- Prior art keywords
- cancer
- treated
- prevented
- pharmaceutically acceptable
- suppressed
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 17
- 201000011510 cancer Diseases 0.000 title claims abstract 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 150000003839 salts Chemical class 0.000 claims abstract 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract 6
- 229960005277 gemcitabine Drugs 0.000 claims abstract 6
- 229940120638 avastin Drugs 0.000 claims abstract 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 3
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 3
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims abstract 2
- 206010060862 Prostate cancer Diseases 0.000 claims abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract 2
- 239000002254 cytotoxic agent Substances 0.000 claims abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 229960003685 imatinib mesylate Drugs 0.000 claims abstract 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims abstract 2
- 210000004324 lymphatic system Anatomy 0.000 claims abstract 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims abstract 2
- 201000001441 melanoma Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims abstract 2
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69367105P | 2005-06-24 | 2005-06-24 | |
| US60/693,671 | 2005-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007143434A true RU2007143434A (ru) | 2009-07-27 |
Family
ID=37575124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007143434/14A RU2007143434A (ru) | 2005-06-24 | 2006-06-13 | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070010527A1 (enExample) |
| EP (1) | EP1893209A2 (enExample) |
| JP (1) | JP2008546777A (enExample) |
| KR (1) | KR20080027275A (enExample) |
| CN (1) | CN101252931A (enExample) |
| AR (1) | AR057403A1 (enExample) |
| AU (1) | AU2006262591A1 (enExample) |
| BR (1) | BRPI0611977A2 (enExample) |
| CA (1) | CA2610209A1 (enExample) |
| CR (1) | CR9539A (enExample) |
| EC (1) | ECSP078015A (enExample) |
| GT (1) | GT200600268A (enExample) |
| IL (1) | IL187792A0 (enExample) |
| MX (1) | MX2007016542A (enExample) |
| NI (1) | NI200700323A (enExample) |
| NO (1) | NO20076075L (enExample) |
| PE (1) | PE20070323A1 (enExample) |
| RU (1) | RU2007143434A (enExample) |
| TW (1) | TW200730177A (enExample) |
| WO (1) | WO2007001839A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007148072A (ru) * | 2005-07-01 | 2009-08-10 | Вайет (Us) | Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения |
| WO2013187967A1 (en) | 2012-06-15 | 2013-12-19 | Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") | Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control |
| WO2017134679A1 (en) * | 2016-02-03 | 2017-08-10 | Msn Laboratories Private Limited | Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof |
| CN107433391B (zh) * | 2017-07-03 | 2020-01-17 | 武汉逸飞激光设备有限公司 | 一种基于图像识别的焊接校准方法及系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6432979B1 (en) * | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| US6384051B1 (en) * | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| UA77200C2 (en) * | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
| RU2006113691A (ru) * | 2003-11-06 | 2007-12-20 | Вайет (Us) | Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml) |
-
2006
- 2006-06-13 BR BRPI0611977-8A patent/BRPI0611977A2/pt not_active IP Right Cessation
- 2006-06-13 RU RU2007143434/14A patent/RU2007143434A/ru not_active Application Discontinuation
- 2006-06-13 EP EP06773093A patent/EP1893209A2/en not_active Withdrawn
- 2006-06-13 CA CA002610209A patent/CA2610209A1/en not_active Abandoned
- 2006-06-13 MX MX2007016542A patent/MX2007016542A/es not_active Application Discontinuation
- 2006-06-13 WO PCT/US2006/023063 patent/WO2007001839A2/en not_active Ceased
- 2006-06-13 JP JP2008518219A patent/JP2008546777A/ja active Pending
- 2006-06-13 KR KR1020077030196A patent/KR20080027275A/ko not_active Withdrawn
- 2006-06-13 CN CNA2006800223605A patent/CN101252931A/zh active Pending
- 2006-06-13 AU AU2006262591A patent/AU2006262591A1/en not_active Abandoned
- 2006-06-22 TW TW095122482A patent/TW200730177A/zh unknown
- 2006-06-22 PE PE2006000716A patent/PE20070323A1/es not_active Application Discontinuation
- 2006-06-22 GT GT200600268A patent/GT200600268A/es unknown
- 2006-06-22 US US11/473,540 patent/US20070010527A1/en not_active Abandoned
- 2006-06-23 AR ARP060102728A patent/AR057403A1/es not_active Application Discontinuation
-
2007
- 2007-11-22 CR CR9539A patent/CR9539A/es not_active Application Discontinuation
- 2007-11-27 NO NO20076075A patent/NO20076075L/no not_active Application Discontinuation
- 2007-11-29 IL IL187792A patent/IL187792A0/en unknown
- 2007-12-14 NI NI200700323A patent/NI200700323A/es unknown
- 2007-12-14 EC EC2007008015A patent/ECSP078015A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO20076075L (no) | 2008-03-18 |
| MX2007016542A (es) | 2008-03-04 |
| IL187792A0 (en) | 2008-11-03 |
| CR9539A (es) | 2008-02-20 |
| NI200700323A (es) | 2008-06-25 |
| WO2007001839A2 (en) | 2007-01-04 |
| AU2006262591A1 (en) | 2007-01-04 |
| WO2007001839A3 (en) | 2007-04-26 |
| ECSP078015A (es) | 2008-01-23 |
| JP2008546777A (ja) | 2008-12-25 |
| CN101252931A (zh) | 2008-08-27 |
| EP1893209A2 (en) | 2008-03-05 |
| PE20070323A1 (es) | 2007-05-04 |
| AR057403A1 (es) | 2007-12-05 |
| US20070010527A1 (en) | 2007-01-11 |
| KR20080027275A (ko) | 2008-03-26 |
| BRPI0611977A2 (pt) | 2010-10-13 |
| GT200600268A (es) | 2007-06-18 |
| TW200730177A (en) | 2007-08-16 |
| CA2610209A1 (en) | 2007-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
| TW200806299A (en) | Treatment of pain | |
| UY26635A1 (es) | Métodos sinérgicos y composiciones para el tratamiento del cáncer | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| EA200200778A1 (ru) | СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ) | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| EA200702445A1 (ru) | Соединения тиазола и способы их применения | |
| TW200420549A (en) | Thiazole derivatives | |
| BRPI0411241A (pt) | agentes terapêuticos úteis para o tratamento de dor | |
| BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
| PH12023550160A1 (en) | Combinations for the Treatment of Cancer | |
| EA201070442A1 (ru) | НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| TW200639159A (en) | Treatment of pain | |
| DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| BR0311491A (pt) | Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero | |
| EA200601249A1 (ru) | Пиперазины, пригодные для лечения боли | |
| MA60154B1 (fr) | Inhibiteurs de line-1 pour traiter une maladie | |
| MX2022011240A (es) | Azálidos de urea inmunomoduladores. | |
| RU2007143434A (ru) | 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний | |
| GEP20257771B (en) | Compounds and compositions as sppl2a inhibitors | |
| ES2284970T3 (es) | Compuestos amina 1,2- y 1,3-diol y su utilizacion para el tratamiento de alzheimer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20101004 |